Bionomics Limited

NASDAQ (USD): Bionomics Limited (BNOX)

Last Price

0.988

Today's Change

+0.038 (4.00%)

Day's Change

0.96 - 1.00

Trading Volume

15,893

Overview

Market Cap

10 Million

Shares Outstanding

10 Million

Avg Volume

109,604

Avg Price (50 Days)

0.98

Avg Price (200 Days)

1.55

PE Ratio

-0.48

EPS

-2.04

Earnings Announcement

30-May-2024

Previous Close

0.95

Open

1.00

Day's Range

0.9601 - 1.0

Year Range

0.84 - 6.41

Trading Volume

16,166

Price Change Highlight

1 Day Change

3.99%

5 Day Change

3.88%

1 Month Change

3.99%

3 Month Change

-20.33%

6 Month Change

-25.16%

Ytd Change

-26.82%

1 Year Change

-57.23%

3 Year Change

-93.29%

5 Year Change

-93.29%

10 Year Change

-93.29%

Max Change

-93.29%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment